The Food and Drug Administration has initiated a nationwide recall of some lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals after finding the tablets were subpotent. The recall covers tablets packaged in 10-count blister packs, sold either on their own or in cartons containing 10 blister packs.
The recall is drawing attention now because levothyroxine sodium tablets are widely used, and people searching for Levothyroxine Recall 2026 want to know whether their medicine is among the affected lots. The FDA said subpotent tablets deliver less medication than intended, which matters when the drug is being used to treat conditions such as hypothyroidism and goiter.
The agency designated the action Class II, a label it uses when affected products may cause temporary, reversible health effects. That does not mean every patient who took the tablets will feel an effect, but it does mean the medicine may not perform as expected for people who rely on a steady dose.
The practical problem is that the recall is limited to some lots, not all levothyroxine sodium tablets, and the available information does not identify the specific lot numbers or expiration dates in the text provided. That leaves patients and pharmacists with the task of checking packaging against the recall notice rather than assuming the medicine is safe or affected.
If a patient has tablets covered by the recall, the advice is straightforward: contact a doctor or pharmacist for guidance on how to proceed, and do not stop taking the medication unless a healthcare provider tells them to. For now, that is the next step that matters most, because the recall turns on which lots were shipped and whether a patient’s supply matches them.
